ArticleInternational journal of cancer2015

Why post-progression survival and post-relapse survival are not appropriate measures of efficacy in cancer randomized clinical trials.

Xabier García-Albéniz et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.